Journal of Hepatology
Volume 49, Issue 2 , Pages 207-216 , August 2008

Identification of novel candidate tumour marker genes for intrahepatic cholangiocarcinoma

  • Ryuhei Nishino

      Affiliations

    • Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Masao Honda

      Affiliations

    • Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Taro Yamashita

      Affiliations

    • Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Hajime Takatori

      Affiliations

    • Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Hiroshi Minato

      Affiliations

    • Pathology Section, Kanazawa University Hospital, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Yoh Zen

      Affiliations

    • Pathology Section, Kanazawa University Hospital, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Motoko Sasaki

      Affiliations

    • Department of Human Pathology, Kanazawa University Graduate School of Medical Science, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Hiroyuki Takamura

      Affiliations

    • Department of Gastroenterologic Surgery, Kanazawa University Graduate School of Medical Science, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Katsuhisa Horimoto

      Affiliations

    • Biological Network Team, Computational Biology Research Centre, National Institute of Advanced Industrial Science and Technology, Japan
    • ,
  • Tetsuo Ohta

      Affiliations

    • Department of Gastroenterologic Surgery, Kanazawa University Graduate School of Medical Science, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Yasuni Nakanuma

      Affiliations

    • Department of Human Pathology, Kanazawa University Graduate School of Medical Science, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • ,
  • Shuichi Kaneko

      Affiliations

    • Department of Gastroenterology, Kanazawa University Graduate School of Medical Science, Kanazawa University, 13-1 Takara-Machi, Kanazawa 920-8641, Japan
    • Corresponding Author InformationCorresponding author. Tel.: +81 76 265 2231; fax: +81 76 234 4250.

Received 5 October 2007 ,Revised 10 March 2008 ,Accepted 24 March 2008.

References 

  1. Shaib Y, El-Serag HB. The epidemiology of cholangiocarcinoma. Semin Liver Dis. 2004;24:115–125
  2. Patel T. Increasing incidence and mortality of primary intrahepatic cholangiocarcinoma in the United States. Hepatology. 2001;33:1353–1357
  3. Taylor-Robinson SD, Toledano MB, Arora S, Keegan TJ, Hargreaves S, Beck A, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48:816–820
  4. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 2002;37:806–813
  5. Davila JA, El-Serag HB. Cholangiocarcinoma: the “other” liver cancer on the rise. Am J Gastroenterol. 2002;97:3199–3200
  6. Marrero JA, Lok AS. Newer markers of hepatocellular carcinoma. Gastroenterology. 2004;127:S113–S119
  7. Johnson DE, Herndier BG, Medeiros LJ, Warnke RA, Rouse RV. The diagnostic utility of the keratin profiles of hepatocellular carcinoma and cholangiocarcinoma. Am J Surg Pathol. 1988;12:187–197
  8. Lai YS, Thung SN, Gerber MA, Chen ML, Schaffner F. Expression of cytokeratins in normal and diseased livers and in primary liver carcinomas. Arch Pathol Lab Med. 1989;113:134–138
  9. Maeda T, Adachi E, Kajiyama K, Sugimachi K, Tsuneyoshi M. Combined hepatocellular and cholangiocarcinoma: proposed criteria according to cytokeratin expression and analyses of clinicopathologic features. Hum Pathol. 1995;26:956–964
  10. Altmannsberger M, Weber K, Holscher A, Schauer A, Osborn M. Antibodies to intermediate filaments as diagnostic tools: human gastrointestinal carcinomas express prekeratin. Lab Invest. 1982;46:520–526
  11. Saintigny P, Coulon S, Kambouchner M, Ricci S, Martinot E, Danel C, et al. Real-time RT-PCR detection of CK19, CK7 and MUC1 mRNA for diagnosis of lymph node micrometastases in non small cell lung carcinoma. Int J Cancer. 2005;115:777–782
  12. Khan SA, Davidson BR, Goldin R, Pereira SP, Rosenberg WM, Taylor-Robinson SD, et al. Guidelines for the diagnosis and treatment of cholangiocarcinoma: consensus document. Gut. 2002;51:VI1–VI9
  13. Gores GJ. Cholangiocarcinoma: current concepts and insights. Hepatology. 2003;37:961–969
  14. Lódi C, Szabó E, Holczbauer A, Batmunkh E, Szı´jártó A, Kupcsulik P, et al. Claudin-4 differentiates biliary tract cancers from hepatocellular carcinomas. Modern Pathol. 2006;19:460–469
  15. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial analysis of gene expression. Science. 1995;270:484–487
  16. Yamashita T, Hashimoto S, Kaneko S, Nagai S, Toyoda N, Suzuki T, et al. Comprehensive gene expression profile of a normal human liver. Biochem Biophys Res Commun. 2000;269:110–116
  17. Yamashita T, Kaneko S, Hashimoto S, Sato T, Nagai S, Toyoda N, et al. Serial analysis of gene expression in chronic hepatitis C and hepatocellular carcinoma. Biochem Biophys Res Commun. 2001;282:647–654
  18. Kawai HF, Kaneko S, Honda M, Shirota Y, Kobayashi K. Alpha-fetoprotein-producing hepatoma cell lines share common expression profiles of genes in various categories demonstrated by cDNA microarray analysis. Hepatology. 2001;33:676–691
  19. Shirota Y, Kaneko S, Honda M, Kawai HF, Kobayashi K. Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology. 2001;33:832–840
  20. Makuuchi M, Belghiti J, Belli G, Fan ST, Lau JW, Ringe B, et al. IHPBA concordant classification of primary liver cancer: working group report. J Hepatobiliary Pancreat Surg. 2003;10:26–30
  21. Yano H, Maruiwa M, Iemura A, Mizogichi A, Kojiro M. Establishment and characterization of a new human extrahepatic bile duct carcinoma cell line (KMBC). Cancer. 1992;69:1664–1673
  22. Kim J, Kim J, Yoon S, Joo J, Lee Y, Lee K, et al. S100A6 protein as a marker for differential diagnosis of cholangiocarcinoma from hepatocellular carcinoma. Hepatol Res. 2002;23:274–286
  23. Lichtinghagen R, Helmbrecht T, Arndt B, Böker KH. Expression pattern of matrix metalloproteinases in human liver. Eur J Clin Chem Clin Biochem. 1995;33:65–71
  24. Miwa S, Miyagawa S, Soeda J, Kawasaki S. Matrix metalloproteinase-7 expression and biologic aggressiveness of cholangiocellular carcinoma. Cancer. 2002;94:428–434
  25. Kumble KD, Hirota M, Pour PM, Vishwanatha JK. Enhanced levels of annexins in pancreatic carcinoma cells of Syrian hamsters and their intrapancreatic allografts. Cancer Res. 1992;52:163–167
  26. Emoto K, Sawada H, Yamada Y, Fujimoto H, Takahama Y, Ueno M, et al. Annexin II overexpression is correlated with poor prognosis in human gastric carcinoma. Anticancer Res. 2001;21:1339–1345
  27. Emoto K, Yamada Y, Sawada H, Fujimoto H, Ueno M, Takayama T, et al. Annexin II overexpression correlates with stromal tenascin-C overexpression: a prognostic marker in colorectal carcinoma. Cancer. 2001;92:1419–1426
  28. Ohuchida K, Mizumoto K, Ohhashi S, Yamaguchi H, Konomi H, Nagai E, et al. S100A11, a putative tumour suppressor gene, is overexpressed in pancreatic carcinogenesis. Clin Cancer Res. 2006;12:5417–5422
  29. Cai L, Mu LN, Lu H, Lu QY, You NC, Yu SZ, et al. Dietary selenium intake and genetic polymorphisms of the GSTP1 and p53 genes on the risk of esophageal squamous cell carcinoma. Cancer Epidemiol Bio Prev. 2006;15:294–300
  30. Xu LL, Shi Y, Petrovics G, Sun C, Makarem M, Zhang W, et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res. 2003;63:4299–4304
  31. ] Karahan N, Güney M, Oral B, Kapucuoglu N, Mungan T. CD24 expression is a poor prognostic marker in endometrial carcinoma. Eur J Gynaecol Oncol. 2006;27:500–504
  32. Wegrowski Y, Pillarisetti J, Danielson KG, Suzuki S, Iozzo RV. The murine biglycan: complete cDNA cloning, genomic organization, promoter function, and expression. Genomics. 1995;30:8–17
  33. Hogemann B, Edel G, Schwarz K, Krech R, Kresse H. Expression of biglycan, decorin and proteoglycan-100/CSF-1 in normal and fibrotic human liver. Pathol Res Pract. 1997;193:747–751
  34. Schneider MR, Wolf E, Hoeflich A, Lahm H. IGF-binding protein-5: flexible player in the IGF system and effector on its own. J Endocrinol. 2002;172:423–440
  35. Butt AJ, Dickson KA, McDougall F, Baxter RC. Insulin-like growth factor-binding protein-5 inhibits the growth of human breast cancer cells in vitro and in vivo. J Biol Chem. 2003;278:29676–29685
  36. Katahira J, Sugiyama H, Inoue N, Horiguchi Y, Matsuda M, Sugimoto N. Clostridium perfringens enterotoxin utilizes two structurally related membrane proteins as functional receptors in vivo. J Biol Chem. 1997;272:26652–26658

☆ The authors declare that they do not have anything to disclose regarding funding from industries or conflict of interest with respect to this manuscript.

PII: S0168-8278(08)00238-9

doi: 10.1016/j.jhep.2008.03.025

Journal of Hepatology
Volume 49, Issue 2 , Pages 207-216 , August 2008

Article Tools

* Image Usage & Resolution